Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $1.67 in the prior trading day, Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $1.7, up 1.80%. In other words, the price has increased by $1.80 from its previous closing price. On the day, 0.78 million shares were traded. LCTX stock price reached its highest trading level at $1.72 during the session, while it also had its lowest trading level at $1.64.
Ratios:
Our goal is to gain a better understanding of LCTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 24 ’25 when DON M BAILEY bought 60,000 shares for $1.60 per share.
DON M BAILEY bought 80,000 shares of LCTX for $97,472 on Sep 10 ’25. On Jan 27 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the Director of the company, bought 7,894,737 shares for $0.76 each. As a result, the insider paid 6,000,000 and bolstered with 49,560,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 391556832 and an Enterprise Value of 352447808. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.19 while its Price-to-Book (P/B) ratio in mrq is 17.77. Its current Enterprise Value per Revenue stands at 32.586 whereas that against EBITDA is -17.912.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.80, which has changed by 1.9298246 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $2.09, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is -1.90%, while the 200-Day Moving Average is calculated to be 42.14%.
Shares Statistics:
The stock has traded on average 1.71M shares per day over the past 3-months and 1120590 shares per day over the last 10 days, according to various share statistics. A total of 230.33M shares are outstanding, with a floating share count of 217.61M. Insiders hold about 5.52% of the company’s shares, while institutions hold 45.01% stake in the company. Shares short for LCTX as of 1767139200 were 24635130 with a Short Ratio of 14.37, compared to 1764288000 on 22837063. Therefore, it implies a Short% of Shares Outstanding of 24635130 and a Short% of Float of 18.959999.
Earnings Estimates
The stock of Lineage Cell Therapeutics Inc (LCTX) is currently being evaluated by 6.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.02, with high estimates of $0.0 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.14 and -$0.42 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.06, with 6.0 analysts recommending between $0.03 and -$0.12.
Revenue Estimates
7 analysts predict $1.96M in revenue. The current quarter. It ranges from a high estimate of $3.68M to a low estimate of -$1.75M. As of. The current estimate, Lineage Cell Therapeutics Inc’s year-ago sales were $2.87M
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $11.63M, while the lowest revenue estimate was $6.2M, resulting in an average revenue estimate of $9.9M. In the same quarter a year ago, actual revenue was $9.5M
